Olga Pechanova

Dr. Olga Pechanova

Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Slovakia
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
Peter KruzliakPeter Kruzliak
Peter Kruzliak
RSRao P. Syamasundar
Rao P. Syamasundar
MNMiroslav Novak
Miroslav Novak
Olga PechanovaOlga Pechanova
Olga Pechanova
GKGabriela Kovacova
Gabriela Kovacova

Verified
Journal Article
Open access
PDF file
Olga PechanovaOlga Pechanova
Olga Pechanova
LPLudovit Paulis
Ludovit Paulis
FSFedor Simko
Fedor Simko
The pineal hormone, melatonin (N-acetyl-5-methoxytryptamine), shows potent receptor-dependent and -independent actions, which participate in blood pressure regulation. The antihypertensive effect of melatonin was demonstrated in experimental and clinical hypertension. Receptor-dependent effects are mediated predominantly through MT1 and MT2 G-protein coupled receptors. The pleiotropic receptor-independent effects of melatonin with a possible impact on blood pressure involve the reactive oxygen species (ROS) scavenging nature, activation and over-expression of several antioxidant enzymes or their protection from oxidative damage and the ability to increase the efficiency of the mitochondrial electron transport chain. Besides the interaction with the vascular system, this indolamine may exert part of its antihypertensive action through its interaction with the central nervous system (CNS). The imbalance between the sympathetic and parasympathetic vegetative system is an important pathophysiological disorder and therapeutic target in hypertension. Melatonin is protective in CNS on several different levels: It reduces free radical burden, improves endothelial dysfunction, reduces inflammation and shifts the balance between the sympathetic and parasympathetic system in favor of the parasympathetic system. The increased level of serum melatonin observed in some types of hypertension may be a counter-regulatory adaptive mechanism against the sympathetic overstimulation. Since melatonin acts favorably on different levels of hypertension, including organ protection and with minimal side effects, it could become regularly involved in the struggle against this widespread cardiovascular pathology.

1 March 2002 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
IBIveta Bernatova
Iveta Bernatova
Olga PechanovaOlga Pechanova
Olga Pechanova
PBPavel Babál
Pavel Babál
SKSona Kyselá
Sona Kyselá
SSSvetoslav Stvrtina
Svetoslav Stvrtina
RARamaroson Andriantsitohaina
Ramaroson Andriantsitohaina
The effects of the red wine polyphenolic compounds (Provinol) on hypertension, left ventricular hypertrophy, myocardial fibrosis, and vascular remodeling were investigated after chronic inhibition of nitric oxide (NO) synthase by administration of NG-nitro-l-arginine methyl ester (l-NAME) to rats. Rats were divided into four groups: a control group, a group treated for 4 wk with l-NAME (40 mg · kg−1· day−1), and two groups treated with l-NAME followed by 3 wk of either spontaneous recovery or recovery with Provinol treatment (40 mg · kg−1· day−1). Administration of Provinol produced a greater readiness of the decrease in blood pressure than that in the spontaneous recovery group. Provinol significantly depressed myocardial fibrosis and expedited the decrease in aortic cross-sectional area, the increase in endothelium-dependent relaxation, and the decrease in contraction of the aorta. These effects of Provinol were associated with a greater increase of NO synthase activity in the left ventricle and the aorta. The present study provides evidence that Provinol accelerates the regression of blood pressure and improves structural and functional cardiovascular changes produced by chronic inhibition of NO synthesis.

1 December 2010 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
MGMonica Galleano
Monica Galleano
Olga PechanovaOlga Pechanova
Olga Pechanova
CFCesar G. Fraga
Cesar G. Fraga
Fruits and vegetables are key foods whose high ingestion is associated with the improvement of numerous pathological conditions, including hypertension. Such health promoting actions have been increasingly ascribed to the antioxidant characteristics of different polyphenols in fruits and vegetables. Consequently, based on this assumption, many beverages and foods rich in polyphenols, grape, tea, cocoa, and soy products and many of their chemical constituents purified, are being studied both, as antioxidants and antihypertensive agents. This paper reviews the current evidence linking high polyphenol consumption with reductions in blood pressure. Basic chemical aspects of flavanols, flavonols, isoflavones and stilbenes, as possible responsible for the observed effects of those foods on blood pressure are included. Human intervention studies by using grapes and wine, cocoa and chocolate, black and green tea, soy products, and purified compounds ((+)-catequin, quercetin, (-)-epigallocatechin gallate) are summarized. The discussed hypothesis, strongly supported by experimental data in animals, is that by regulating nitric oxide bioavailability, polyphenols present in fruits and vegetables affect endothelial function and as a consequence, blood pressure. Even when data are not definitive and many questions remain open, the whole evidence is encouraging to start considering diets that can provide benefits to hypertensive subjects, and those benefits will be more significant in people that do not have controlled his/her elevated blood pressure.

1 August 2004 in Journal Of Hypertension
Verified
Journal Article
Closed access
Olga PechanovaOlga Pechanova
Olga Pechanova
IBIveta Bernatova
Iveta Bernatova
PBPavel Babal
Pavel Babal
MMM Carmen Martínez
M Carmen Martínez
SKSona Kyselá
Sona Kyselá
RARamaroson Andriantsitohaina
Ramaroson Andriantsitohaina
Objective Red wine polyphenols have been reported to possess beneficial properties for preventing cardiovascular diseases but their effects on hemodynamic and functional cardiovascular changes during inhibition of nitric oxide (NO) synthesis have not been elucidated. Design The effects of the red wine polyphenols, Provinols, on arterial hypertension as well as left ventricular (LV) hypertrophy, myocardial fibrosis and vascular remodeling were investigated in rats during chronic inhibition of nitric oxide synthase (NOS) activity. Rats were divided into four groups: a control group, a group treated with NG-nitro-l-arginine methyl ester (L-NAME) (40 mg/kg per day), a group receiving Provinols (40 mg/kg per day) alone or Provinols plus L-NAME. Results Provinols markedly reduced the increase in both blood pressure and protein synthesis in the heart and aorta caused by chronic inhibition of NO synthesis. Provinols reduced myocardial fibrosis even though it did not affect LV hypertrophy. In addition, Provinols prevented aortic thickening and corrected the augmented reactivity of the aorta to norepinephrine and the attenuated endothelium-dependent relaxation to acetylcholine in NO-deficient rats. These alterations were associated with an increase of NOS activity, a moderate enhancement of endothelial NOS expression and a reduction of oxidative stress in the LV and aorta. Conclusion Our results provide evidence that Provinols partially prevents L-NAME-induced hypertension, cardiovascular remodeling and vascular dysfunction via the increase of NO-synthase activity and prevention of oxidative stress. Thus, the beneficial effects of plant polyphenols in prevention of hypertension may result from their complex influence on the NO balance in the cardiovascular system.

1 June 2021 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
MBMonika Barteková
Monika Barteková
AAAdriana Duriš Adameova
Adriana Duriš Adameova
AGAnikó Görbe
Anikó Görbe
KFKristína Ferenczyová
Kristína Ferenczyová
Olga PechanovaOlga Pechanova
Olga Pechanova
ZGZoltán Giricz
Zoltán Giricz
Cardiometabolic diseases (CMDs) are metabolic diseases (e.g., obesity, diabetes, atherosclerosis, rare genetic metabolic diseases, etc.) associated with cardiac pathologies. Pathophysiology of most CMDs involves increased production of reactive oxygen species and impaired antioxidant defense systems, resulting in cardiac oxidative stress (OxS). To alleviate OxS, various antioxidants have been investigated in several diseases with conflicting results. Here we review the effect of CMDs on cardiac redox homeostasis, the role of OxS in cardiac pathologies, as well as experimental and clinical data on the therapeutic potential of natural antioxidants (including resveratrol, quercetin, curcumin, vitamins A, C, and E, coenzyme Q10, etc.), synthetic antioxidants (including N-acetylcysteine, SOD mimetics, mitoTEMPO, SkQ1, etc.), and promoters of antioxidant enzymes in CMDs. As no antioxidant indicated for the prevention and/or treatment of CMDs has reached the market despite the large number of preclinical and clinical studies, a sizeable translational gap is evident in this field. Thus, we also highlight potential underlying factors that may contribute to the failure of translation of antioxidant therapies in CMDs.